Is This the Best Precision Medicine Stock to Buy?
Foundation Medicine (NASDAQ: FMI) scans patient samples for myriad genetic mutations, and that insight is allowing increasingly more oncologists to match their cancer patients with treatments that have the best shot at success.
Given it's only early innings for personalized medicine, and the peak opportunity associated with it could total billions of dollars annually, let's learn a bit more about this company.
Our understanding of cancer is morphing beyond its anatomical location to its genetic cause, and as we gain greater insight into genetic mutations associated with cancer, genetic screening could become standard in determining the appropriate treatment.
Source: Fool.com
